* HYBRIGENICS *
1998 - IDF
Paris
www.hybrigenics.com Discovery, Drugs
(also, Services, Research)
Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs), Ubiquitin
Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions
Clients: Prescribers
contact@hybrigenics.com
Age: 12 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Academic |
Managing Dir.-CEO: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)]
Clin.Dir.-CMO: Dufourt-Lamartinie (Jean-François) [Ph.D., ex-IGR, BioAlliance]
Oper.Dir.-COO: Petitville (Didier) [ex-Institut Pasteur]
I.T.Dir.-CIO: Boissy (Guillaume) [Ph.D. molecular biophysics, ex-INSA]
Fin.Dir.-CFO: Cohen, Eric [Ms. finance (Dauphine), MBA (LBS), ex-Teva, Mazars, CityJeux, Radio BFM]
BusDev:
Financers (Hist.): Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public | Turnover (M€) : 3.64 (2008)
Total funding (M€) : n.a.
Last funding (M€) : 2.7
Focus : Cancers
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .12 | Financing : 2.735 M€ issued for private investors, i.e. 10.5% capital, for inecalcitol development costs (in complement to Yorkville) | RFIN | [11 years] |
| 2009 .09 | Financing : up to 5 M€ through privileged new shares to Yorkville, over 3 years | RFIN | [11 years] |
| 2009 .09 | Partnering research agreement with yeast two-hybrid contract of 1.5 M€, for services to an American multinational life sciences company during 3 years | R&D | [11 years] |
| 2009 .05 | Set-up of Hybrigenics Services, a subsidiary owned by Rémi Delansorne | ORGC | [11 years] |
| 2009 .02 | Financing : 0.4 M€ by E.U. to participate in Masterswitch European project and screen inhibitors of protein interaction in the field of chronic inflammatory diseases | RFIN | [11 years] |
| 2008 .12 | Patent : granted on protease inhibitors specific to ubiquitin (cancer) | LEGAL | [10 years] |
| 2008 .09 | Financing (no interest loan) : 1.4 M€, by OSEO, to support its ongoing clinical development program of inecalcitol in prostate cancer | DEBT | [10 years] |
| 2007 .12 | Listing on Alternext : 6.2 M€ | PBO | [9 years] |
| 2005 .09 | Nomination : Rémi Delansorne, as CEO (previously CSO since 2004), replacing Donny Strosberg | ORGN | [7 years] |
| 2003 .05 | Acquisition of Semaia (Holland), a biotech focused on oncology | ACQ+ | [5 years] |
| 2002 .04 | 3rd round-financing : 16.8 M€, led by Life Science Partners, with Banexi V.P., C.F. Edmond de Rothschild, and previous shareholders | RFINC | [4 years] |
| 2000 .10 | 2nd round-financing : 19.5 M€, led by Alafi Capital, Lombard Odier, Medicis, Rendex, Sofindev, and previous shareholders | RFINB | [2 years] |
| 1999 .06 | 1st round-financing : 9.1 M€, led by Auriga Partners, IMH, HealthCap, and previous shareholders | RFINA | [1 year] |
| 1998 .05 | Seed financing : 1 M€, by Apax Partners, Altamir | SFIN | [0 year] |
| 1998 .04 | Licensing-in of any discovery by Institut Pasteur on protein-protein interaction, with right of first refusal and exclusivity | LICIN | [0 year] |
| 1998 .01 | Company founded by Prof. Arthur Donny Strosberg (CEO), Pierre Legrain, Jacques Camonis, and Richard Benarous | ORGF | [0 year] | Actualisation / Updating: 04-Janv-2010 |
|
